HIM
CTKB icon

Hillsdale Investment Management’s Cytek Biosciences CTKB Stock Holding History

Hillsdale Investment Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-344,529
Closed -$3.52M – 584
2022
Q4 		$3.52M Hold
344,529
– – 0.3% 127
2022
Q3 		$5.07M Buy
+344,529
New +$4.48M 0.46% 69

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Hillsdale Investment Management's CTKB Position: Q1 2023 in Review

Hillsdale Investment Management sold out of Cytek Biosciences (CTKB) in Q1 2023, closing a stake of 344,529 shares — an estimated $3.52M sold.

Hillsdale Investment Management first reported a position in CTKB in Q3 2022 and held it in 2 quarters. The position peaked at $5.07M in Q3 2022. 102 funds tracked by Wall St. Rank hold CTKB as of Q1 2023.

  • Hillsdale Investment Management reported no remaining Cytek Biosciences position as of Q1 2023 after selling out during the quarter.
  • Hillsdale Investment Management sold 344,529 Cytek Biosciences shares in Q1 2023, an estimated $3.52M.
  • Hillsdale Investment Management first reported a position in Cytek Biosciences in Q3 2022 and held it in 2 quarters.
  • Hillsdale Investment Management's Cytek Biosciences position peaked at $5.07M in Q3 2022.
  • 102 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2023.

Based on Hillsdale Investment Management's 13F filing for Q1 2023, filed 10 May 2023.